Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage.
Aaron S KesselheimCarolyn L TreasureBarbara KoenigPublished in: PLoS medicine (2017)
Aaron Kesselheim and colleagues examine orphan-designated drugs approved between 2009 and 2015 in the United States.